What is Progenesis?
Founded in 2015 and based in La Jolla, California, Progenesis specializes in preimplantation genetic testing (PGT) and related assessments crucial for In Vitro Fertilization (IVF) procedures. Their service portfolio includes Previda (PGT-A), Previda-DX (PGT-M/SR), and mitochondrial DNA assessments (MitoSure), complemented by genetic counseling via their online portal, Revela. The company leverages advanced technology and a team of genetic experts to support individuals and couples in their family planning journeys, providing comprehensive insights into reproductive health.
How much funding has Progenesis raised?
Progenesis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Progenesis?
With the recent influx of capital from a large-scale, late-stage funding round, Progenesis is poised for significant expansion and further technological development. This strategic backing is expected to fuel advancements in their genetic testing platforms and potentially broaden their market reach. The company's focus on specialized genetic assessments for IVF positions it to capitalize on the growing demand for assisted reproductive technologies and personalized genetic insights.
See full Progenesis company page
